Maffey-Steffan, Johanna
Scarpa, Lorenza
Svirydenka, Anna
Nilica, Bernhard
Mair, Christian
Buxbaum, Sabine
Bektic, Jasmin
von Guggenberg, Elisabeth
Uprimny, Christian
Horninger, Wolfgang
Virgolini, Irene
Funding for this research was provided by:
University of Innsbruck and Medical University of Innsbruck
Article History
Received: 25 July 2019
Accepted: 15 October 2019
First Online: 27 November 2019
Change Date: 20 December 2019
Change Type: Correction
Change Details: The author name Bernhard Nilica was inadvertently interchanged in the original version of this article.
Compliance with Ethical Standards
:
: The authors declare that they have no conflicts of interest.
: The application of <sup>177</sup>Lu-PSMA-617 was approved by the institutional review tumor board and all patients gave written informed consent to therapy and imaging studies. All patients received <sup>177</sup>Lu-PSMA-617 under compassionate use condition according to the updated Declaration of Helsinki [], prepared according to the Austrian Medicinal Products Act, AMG §8 and §62 []. All patients were informed about the experimental nature of the <sup>177</sup>Lu-PSMA-617 therapy and no systematic patient selection was performed. All regulations of the Austrian Agency for Radiation Protection were observed [].
: According to the Austrian Laws, for this type of study, a formal consent is not required.